A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

This trial is testing zanubrutinib (a BTK inhibitor pill) in combination with an infusion regimen of polatuzumab vedotin, bendamustine, and rituximab (called pola-BR) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) — an aggressive blood cancer that has come back or stopped responding to prior treatment. **You may be eligible if...** - You are 18–75 years old with confirmed DLBCL that has returned or not responded after initial treatment - You have at least one measurable lymphoma lesion - You are in reasonable health (ECOG 0-2) with estimated survival of at least 3 months - You have adequate blood counts, liver, and kidney function **You may NOT be eligible if...** - Your lymphoma has spread to the brain (CNS involvement) - You have previously received an organ transplant or stem cell transplant - You have another active cancer, HIV, or active hepatitis B or C - You have significant bleeding problems or are on warfarin-type blood thinners - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.